Abstract
A small series of piperidine analogs that effectively activate glycogen synthase (GS) was prepared in WO2011058122. The treatment or prophylaxis of metabolic disease and disorders by these novel GS activators is claimed. These compounds represent further variations around a structural motif explored in the prior patent publications by Roche.
MeSH terms
-
Animals
-
Drug Design
-
Glycogen Synthase / drug effects*
-
Glycogen Synthase / metabolism
-
Humans
-
Metabolic Diseases / drug therapy
-
Metabolic Diseases / enzymology
-
Metabolic Diseases / physiopathology
-
Patents as Topic
-
Piperidines / chemistry
-
Piperidines / pharmacology*
-
Pyrrolidines / chemistry
-
Pyrrolidines / pharmacology*
Substances
-
Piperidines
-
Pyrrolidines
-
Glycogen Synthase